Complex Partial Seizures

Also known as: Partial complex seizure / Complex partial seizures / Partial complex seizures / Complex partial Seizure / Partial seizures, complex / Psychomotor fit

DrugDrug NameDrug Description
DB00754EthotoinEthotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
DB00252PhenytoinAn anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
DB00313Valproic AcidValproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
DrugDrug NameTargetType
DB00754EthotoinSodium channel protein type 5 subunit alphatarget
DB00754EthotoinNuclear receptor subfamily 1 group I member 2target
DB00754EthotoinThyroxine-binding globulincarrier
DB00252PhenytoinSodium channel protein type 5 subunit alphatarget
DB00252PhenytoinSodium channel protein type 1 subunit alphatarget
DB00252PhenytoinCytochrome P450 2C8enzyme
DB00252PhenytoinCytochrome P450 2C19enzyme
DB00252PhenytoinCytochrome P450 2C9enzyme
DB00252PhenytoinCytochrome P450 2B6enzyme
DB00252PhenytoinCytochrome P450 3A5enzyme
DB00252PhenytoinSerum albumincarrier
DB00252PhenytoinCytochrome P450 3A4enzyme
DB00252PhenytoinSolute carrier organic anion transporter family member 1C1transporter
DB00252PhenytoinMultidrug resistance protein 1transporter
DB00252PhenytoinCanalicular multispecific organic anion transporter 1transporter
DB00252PhenytoinCytochrome P450 11B1, mitochondrialenzyme
DB00252PhenytoinCytochrome P450 2C18enzyme
DB00252PhenytoinCytochrome P450 3A7enzyme
DB00252PhenytoinNuclear receptor subfamily 1 group I member 2target
DB00252PhenytoinSodium channel subunit beta-1target
DB00252PhenytoinSodium channel protein type 3 subunit alphatarget
DB00252PhenytoinUDP-glucuronosyltransferase 1-1enzyme
DB00252PhenytoinUDP-glucuronosyltransferase 1-6enzyme
DB00252PhenytoinUDP-glucuronosyltransferase 1-9enzyme
DB00252PhenytoinCytochrome P450 2D6enzyme
DB00252PhenytoinThyroxine-binding globulincarrier
DB00313Valproic AcidHistone deacetylase 9target
DB00313Valproic AcidShort/branched chain specific acyl-CoA dehydrogenase, mitochondrialtarget
DB00313Valproic AcidCytochrome P450 2A6enzyme
DB00313Valproic AcidCytochrome P450 2B6enzyme
DB00313Valproic AcidCytochrome P450 2C9enzyme
DB00313Valproic AcidSolute carrier family 22 member 5transporter
DB00313Valproic AcidSolute carrier family 22 member 6transporter
DB00313Valproic AcidSolute carrier family 22 member 8transporter
DB00313Valproic AcidMonocarboxylate transporter 1transporter
DB00313Valproic AcidSolute carrier family 22 member 7transporter
DB00313Valproic AcidCytochrome P450 3A5enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 1-9enzyme
DB00313Valproic AcidProstaglandin G/H synthase 1enzyme
DB00313Valproic AcidCytochrome P450 1A2enzyme
DB00313Valproic AcidCytochrome P450 2C19enzyme
DB00313Valproic AcidCytochrome P450 2C8enzyme
DB00313Valproic AcidCytochrome P450 3A4enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 1-4enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 1-8enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 1-10enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 1-6enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 1-3enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 2B7enzyme
DB00313Valproic AcidUDP-glucuronosyltransferase 2B15enzyme
DB00313Valproic Acid2-oxoglutarate dehydrogenase, mitochondrialtarget
DB00313Valproic AcidSuccinate-semialdehyde dehydrogenase, mitochondrialtarget
DB00313Valproic AcidSodium channel proteintarget
DB00313Valproic AcidHistone deacetylase 2target
DB00313Valproic AcidPeroxisome proliferator-activated receptor alphatarget
DB00313Valproic AcidPeroxisome proliferator-activated receptor deltatarget
DB00313Valproic AcidPeroxisome proliferator-activated receptor gammatarget
DB00313Valproic AcidSerum albumincarrier
DB00313Valproic AcidUDP-glucuronosyltransferase 1-1enzyme
DB00313Valproic AcidSolute carrier organic anion transporter family member 2B1transporter
DrugDrug NamePhaseStatusCount
DB12338Carisbamate3Completed1
DB01080Vigabatrin4Terminated1